Charles Schwab’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-11,178
Closed -$167K 3648
2022
Q4
$167K Hold
11,178
﹤0.01% 3211
2022
Q3
$92K Sell
11,178
-6,002
-35% -$46.1K ﹤0.01% 3232
2022
Q2
$113K Hold
17,180
﹤0.01% 3279
2022
Q1
$97K Hold
17,180
﹤0.01% 3421
2021
Q4
$81K Hold
17,180
﹤0.01% 3464
2021
Q3
$107K Buy
+17,180
New +$103K ﹤0.01% 3374
2021
Q2
Sell
-55,282
Closed -$405K 3637
2021
Q1
$405K Sell
55,282
-2,582
-4% -$22.3K ﹤0.01% 3149
2020
Q4
$334K Buy
57,864
+9,719
+20% +$55.6K ﹤0.01% 3117
2020
Q3
$286K Buy
48,145
+15,936
+49% +$78.8K ﹤0.01% 3045
2020
Q2
$166K Buy
+32,209
New +$203K ﹤0.01% 3194
2020
Q1
Sell
-2,863
Closed -$18K 3257
2019
Q4
$18K Hold
2,863
﹤0.01% 3162
2019
Q3
$25K Hold
2,863
﹤0.01% 3152
2019
Q2
$20K Sell
2,863
-20,103
-88% -$172K ﹤0.01% 3201
2019
Q1
$189K Hold
22,966
﹤0.01% 3033
2018
Q4
$368K Buy
22,966
+1,153
+5% +$25.4K ﹤0.01% 2869
2018
Q3
$723K Hold
21,813
﹤0.01% 2719
2018
Q2
$493K Buy
21,813
+18,950
+662% +$449K ﹤0.01% 2809
2018
Q1
$84K Hold
2,863
﹤0.01% 3052
2017
Q4
$80K Buy
+2,863
New +$88.9K ﹤0.01% 3042
2016
Q3
Sell
-1,510
Closed -$15K 3056
2016
Q2
$15K Hold
1,510
﹤0.01% 3094
2016
Q1
$14K Hold
1,510
﹤0.01% 3050
2015
Q4
$20K Hold
1,510
﹤0.01% 3088
2015
Q3
$19K Hold
1,510
﹤0.01% 3081
2015
Q2
$27K Hold
1,510
﹤0.01% 3078
2015
Q1
$22K Hold
1,510
﹤0.01% 3076
2014
Q4
$13K Hold
1,510
﹤0.01% 3102
2014
Q3
$17K Hold
1,510
﹤0.01% 3066
2014
Q2
$28K Sell
1,510
-6,490
-81% -$84.4K ﹤0.01% 3075
2014
Q1
$120K Hold
8,000
﹤0.01% 3024
2013
Q4
$148K Hold
8,000
﹤0.01% 3023
2013
Q3
$167K Sell
8,000
-2,380
-23% -$54.5K ﹤0.01% 2966
2013
Q2
$266K Buy
+10,380
New +$444K ﹤0.01% 2779

Charles Schwab's AVEO Position: Q1 2023 in Review

Charles Schwab sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 11,178 shares — an estimated $167K sold.

Charles Schwab first reported a position in AVEO in Q2 2013 and held it in 32 quarters. The position peaked at $723K in Q3 2018. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Charles Schwab reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Charles Schwab sold 11,178 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $167K.
  • Charles Schwab first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
  • Charles Schwab's AVEO Pharmaceuticals, Inc. position peaked at $723K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.